Loading
VB15010 is an experimental pill targeting the PARP1 DNA-repair enzyme.
NCT06819215 is a recruiting phase 1/2 study of VB15010 in advanced solid tumours. The registry describes PARP1 inhibition; there is no marketing approval or comparative clinical efficacy claim here.
The registry describes VB15010 as a PARP1 inhibitor. Connects to PARP.
1.VB15010 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VB15010" OR ABSTRACT:"VB15010") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VB15010, not a curated reading list.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tags pipeline, registry-only.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer and the tags pipeline, registry-only.
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tags pipeline, registry-only.
Shares PARP and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/